Q-omics provides the consensus-scored MXRA5Y profile across patient tissues and cancer cell-line models. MXRA5Y expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MXRA5Y is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MXRA5Y RNA expression shows 14,948 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where MXRA5Y shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MXRA5Y — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MXRA5Y survival associations across molecular data types. MXRA5Y RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MXRA5Y RNA expression–survival associations across cancer types. High MXRA5Y expression shows unfavorable associations in ACC, GBM, MESO and UVM, but favorable associations in LUAD and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MXRA5Y RNA expression.
This table summarizes MXRA5Y tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MXRA5Y. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MXRA5Y shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, BRCA, LUSC and STAD. The HNSC box plot shows higher MXRA5Y RNA expression in tumor versus normal tissue (log2 FC = +0.385, t-test p < 0.001).
This table shows molecular features associated with MXRA5Y in patient tissues and cancer cell lines. In patient samples, MXRA5Y shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
